Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …

This review discusses the development and uses of imatinib mesylate, a protein tyrosine
kinase inhibitor useful in the treatment of chronic myelogenous leukemia and …

Results of 2 parallel phase 2 trials of transplantation of unrelated umbilical cord blood (UCB)
or bone marrow (BM) from HLA-haploidentical relatives provided equipoise for direct …

Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …

We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide
(Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient …

Allogeneic marrow transplantation can cure sickle cell disease; however, HLA-matched
donors are difficult to find, and the toxicities of myeloablative conditioning are prohibitive for …

Related HLA-haploidentical blood or marrow transplantation (BMT) with high-dose
posttransplantation cyclophosphamide (PTCy) is being increasingly used because of its …

Purpose Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using
post-transplantation cyclophosphamide (PT-Cy) is increasingly used in patients lacking HLA …

The National Marrow Donor Program (NMDP) maintains a registry of approximately 4 million
volunteer unrelated donors for patients in need of a stem cell transplant. When several …

Background Data regarding the outcome of cord-blood transplantation in adults are scant,
despite the fact that these grafts are increasingly used in adults. Methods We compared the …